PBYI News and Press, Puma Biotechnology Inc From 03/02/23

Puma Biotechnology press release ( NASDAQ: PBYI ): Q4 Non-GAAP EPS of -$0.07. Revenue of $65.7M (+18.6% Y/Y) beats by $8.64M . Sees Q1 2023 net product revenue of $43M to $46M, royalty revenue of $4M to $6M. Sees FY 2023 net product revenue of $205M to $210M, royalty r...

Puma Biotechnology ( NASDAQ: PBYI ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, after market close. The consensus EPS Estimate is $0.10 (-52.4% Y/Y) and the consensus Revenue Estimate is $57.06M (+3.0% Y/Y). Over the last 2 years, PBYI has beaten EPS...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen’s 43 rd Annual Health Care Conference, which will be held March 6 – 8, 2023 at the Boston Ma...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s super-easy to look for large-cap stocks – those names that seemingly everyone knows, or FAANG stocks that get plenty of attention from both analysts and retail investors. But if you want to stand out from t...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the release of its fourth quarter and full year 2022 financial results. The call may be accessed by dialing 1-877-709-8150 (do...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX ® ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m. PST/2:00 p.m. EST on January 19 at the virtual B. Riley Securities’...

Summary PBYI recently bounced from its November lows, rallying from $2 to $5.16 in a matter of weeks. It reported revenue growth of 23.5% YoY to $57.1mm, also a sequential decline of ~$2.4mm from Q2 FY22. PBYI management also increased FY22 guidance from the top to bottom lines. ...

Summary Neratinib has performed poorly over the years. The reason is marginal efficacy, terrible diarrhea, and strong competition. I have no expectation that PBYI will ever be a long term hold. I covered Puma Biotechnology ( PBYI ) more than 5 years ago, and I am n...

Shares of Puma Biotechnology (NASDAQ: PBYI) were up as much as 13% this week. As of Thursday afternoon, they were still up more than 10% for the week, according to data from S&P Global Intelligence. The biotech company, which focuses on cancer therapies, closed at $4.40 a ...